Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Open-label, Phase II, Dose/Schedule Optimisation Study of NUC-3373/Leucovorin/Irinotecan Plus Bevacizumab (NUFIRI-bev) Versus 5-FU/Leucovorin/Irinotecan Plus Bevacizumab (FOLFIRI-bev) for the Treatment of Patients With Previously Treated Unresectable Metastatic Colorectal Cancer

NCT05678257 is registered in ClinicalTrials.gov with NuCana plc as lead sponsor.

NCT NCT05678257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05678257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Open-label, Phase II, Dose/Schedule Optimisation Study of NUC-3373/Leucovorin/Irinotecan Plus Bevacizumab (NUFIRI-bev) Versus 5-FU/Leucovorin/Irinotecan Plus Bevacizumab (FOLFIRI-bev) for the Treatment of Patients With Previously Treated Unresectable Metastatic Colorectal Cancer
Lead sponsor
NuCana plc
Phase
Phase 2
Overall status
Terminated
Start date
April 18, 2023
Completion date
August 29, 2024
Enrollment
180 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, colorectal cancer, colorectal cancer metastatic, colorectal neoplasms, neoplasm, colorectal